Finance

Lists
Why is KYTX down 5,01%?
Dive Deeper
KYTX:NASDAQ
Kyverna Therapeutics Inc
5,90 $
-5,01%
(-0,31) 1D
13 հոկ, 12:41:34 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
6,17 $
High
6,17 $
Low
5,87 $
Mkt. cap
364,82 մլն
Avg. vol.
918,10 հզր
Volume
510,37 հզր
52-wk high
13,67 $
52-wk low
5,87 $
EPS
-2,94 $
Shares outstanding
61,84 մլն
No. of employees
149
Open
6,17 $
High
6,17 $
Low
5,87 $
Mkt. cap
364,82 մլն
Avg. vol.
918,10 հզր
Volume
510,37 հզր
52-wk high
13,67 $
52-wk low
5,87 $
EPS
-2,94 $
Shares outstanding
61,84 մլն
No. of employees
149
News stories
From web sources and news partners
About Kyverna Therapeutics Inc
CEO-
Employees149
Founded2018
HeadquartersԷմերիվիլ, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitekyvernatx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KYTX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current 5,90 $
33,00 $ (+459,41%)
Average
30,33 $ (+414,15%)
Lowest
25,00 $ (+323,79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
25,00 $
+323,8%
09/25/2026
Derek Archila
Wells Fargo
Buy
Reiterated
33,00 $
+459,4%
09/25/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/24/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
33,00 $
+459,4%
08/12/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/12/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
29,00 $
+391,6%
05/13/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
30,00 $
+408,6%
03/30/2026
Last report
11 օգս, 2026 թ.
Fiscal period
Q2 2026
-0,63 $ / -0,68 $
+7,28%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
30,46 մլն
-103,71 մլն
30,07 մլն
-
Cost of revenue
30,46 մլն
-103,71 մլն
30,07 մլն
-
Research and development expenses
-
133,72 մլն
-
24,79 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,27 մլն
9,27 մլն
11,29 մլն
14,77 մլն
Operating expense
8,27 մլն
142,99 մլն
11,29 մլն
39,56 մլն
Total operating expenses
38,73 մլն
39,28 մլն
41,37 մլն
39,56 մլն
Operating income
-38,73 մլն
-39,28 մլն
-41,37 մլն
-39,56 մլն
Other non operating income
-53,00 հզր
17,00 հզր
-21,00 հզր
-18,00 հզր
EBT including unusual items
-36,79 մլն
-37,80 մլն
-39,73 մլն
-38,32 մլն
EBT excluding unusual items
-36,79 մլն
-37,80 մլն
-39,73 մլն
-38,32 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36,79 մլն
-37,80 մլն
-39,73 մլն
-38,32 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,85
-0,80
-0,66
-0,63
Interest and investment income
2,00 մլն
1,90 մլն
2,33 մլն
1,93 մլն
Interest expense
-7,00 հզր
-444,00 հզր
-667,00 հզր
-674,00 հզր
Net interest expenses
1,99 մլն
1,46 մլն
1,66 մլն
1,26 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-37,84 մլն
-38,91 մլն
-41,02 մլն
-39,12 մլն
Gain or loss from assets sale
40,00 հզր
20,00 հզր
-
-47,00 հզր
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps